Safety and efficacy of sparsentan versus irbesartan in focal segmental glomerulosclerosis and IgA nephropathy: a systematic review and meta-analysis of randomized controlled trials

Press/Media

Period27 Sept 2024

Media coverage

1

Media coverage

  • TitleSafety and efficacy of sparsentan versus irbesartan in focal segmental glomerulosclerosis and IgA nephropathy: a systematic review and meta-analysis of randomized controlled trials
    Media name/outletBMC Nephrology
    Country/TerritoryUnited Kingdom
    Date27/09/24
    PersonsKA HOU CHAN